Dry Age-related Macular Degeneration Clinical Trial
Official title:
A Multi-Center Registry Study to Assess the Safety and Effectiveness of Photobiomodulation in Participants With Dry Age-Related Macular Degeneration (EUROLIGHT)
The EUROLIGHT study is being conducted to collect real life data for the safety and effectiveness of PBM in dry AMD, in routine clinical practice both retrospectively and prospectively.
This is a multi-center, retrospective and prospective registry study on the use of the Valeda® PBM system as a treatment for visual improvement in participants with dry AMD. The target is at least 25 participants/site in up to 20 participating sites in Europe. Participants will or will have received nine non-invasive, short treatments over three to four weeks starting at Baseline (BL), with up to five additional rounds of treatment every four to six months, or as determined by the Investigator. Standard visual outcome measurements collected will include visual acuity (either ETDRS BCVA or LogMAR) prior to and following treatment. OCT and Fundus Autofluorescence (FAF) imaging of the retina should be taken at screening, and after each round of treatment. As this is a registry study, missing ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03046407 -
Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human Embryonic Stem Cells
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04566445 -
HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
|
Phase 2 | |
| Recruiting |
NCT04339764 -
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05536752 -
QA102 Phase II Study in Subjects With Dry AMD
|
Phase 2 | |
| Active, not recruiting |
NCT04065490 -
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)
|
N/A | |
| Recruiting |
NCT06229665 -
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)
|
Phase 2/Phase 3 | |
| Completed |
NCT01002950 -
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
|
Phase 2 | |
| Active, not recruiting |
NCT03333954 -
Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular Degeneration
|
N/A | |
| Completed |
NCT05667688 -
Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Aged 50-85
|
Phase 1 | |
| Completed |
NCT01379560 -
A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration
|
Phase 2 | |
| Completed |
NCT03144999 -
Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59
|
Phase 1 | |
| Withdrawn |
NCT04511936 -
Microcurrent Stimulation for Dry Age-related Macular Degeneration
|
N/A | |
| Withdrawn |
NCT04358471 -
Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA)
|
Phase 2 | |
| Terminated |
NCT04643886 -
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration
|
Phase 2 | |
| Not yet recruiting |
NCT05418231 -
Observation of the Natural Course of Age-related Macular Degeneration
|
||
| Recruiting |
NCT00926861 -
Posterior Macular Adhesion: A Potential Risk Factor for Non-exudative Age Related Macular Degeneration (AMD) to Develop Exudative AMD
|
N/A | |
| Active, not recruiting |
NCT04437368 -
EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
|
Phase 2 | |
| Active, not recruiting |
NCT03894020 -
GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)
|
||
| Not yet recruiting |
NCT04875234 -
Vision Improvement for Legally Blind Dry AMD Patients
|
||
| Recruiting |
NCT02755428 -
Subretinal Transplantation of Retinal Pigment Epitheliums in Treatment of Age-related Macular Degeneration Diseases
|
Phase 1/Phase 2 |